Updates from the 2022 American Society of Hematology Annual Meeting

The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 300 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific Advisory Board (SAB) and grantees, contributing to an abstract presented at the conference.

Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provides a critical forum for leading hematologists/oncologists to present their findings to over 20,000 of their peers. Among the distinguished scientists attending, more than 90 LRF-affiliated scientists presented at the 2022 ASH Annual Meeting.

In addition to LRF’s representation through presentations, LRF researchers contributed to 705 abstracts across all hematology and 522 lymphoma-related abstracts. Eighty percent of LRF scholars — participants in LRF’s Lymphoma Scientific Research Mentoring Program (LSRMP) – authored at least one abstract at ASH.

Highlights from ASH 2022:

• Short-course Brentuximab Vedotin with Chemotherapy is Highly Active in Early-Stage Bulky Hodgkin Lymphoma
• Quality of Life Improves Quickly in Survivors of Aggressive Lymphomas
• Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
• Next-Generation BTKi Zanubrutinib Demonstrates Improved Efficacy and Tolerability Compared with Ibrutinib
• Updated Index Improves Prognostication for Survival in Advanced-Stage Hodgkin Lymphoma
• Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
• Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy
• High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Plus Venetoclax